BMS’ Mavacamten Receives the NICE Recommendation for the Treatment of Obstructive Hypertrophic Cardiomyopathy
- NICE has published final draft guidance recommending mavacamten as an add-on to standard care on the NHS use for the treatment of obstructive hypertrophic cardiomyopathy. Additionally, 7000 people will now be able to access the treatment on the NHS
- The clinical trial evidence suggested that mavacamten + SoC was found to be more effective over SoC alone, and might prevent or delay the need for invasive surgery
- Camzyos (mavacamten), the first cardiac myosin inhibitor was approved in the US for the treatment of adults with symptomatic NYHA class II-III obstructive HCM to improve functional capacity and symptoms
Ref: Nice | Image: BMS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.